Literature DB >> 11043151

Neuropsychological approaches to treatment policy issues in phenylketonuria.

P Griffiths1.   

Abstract

UNLABELLED: Neuropsychological research conducted so far on treatment factors in phenylketonuria suggests that dietary cessation at age 6 is too early. However, continuation of diet until age 10 appears to provide protection against subsequent hyperphenylalaninaemia in the domains of perception, memory and motor skill if concentrations remain at least below 1200 mumol/l thereafter. Levels in the range 360 mumol/l to 600 mumol/l appear to constitute a hazard for executive skill during the pre-school period but in the primary school years the risk diminishes. Levels above 900 mumol/l in early adolescence and adulthood may affect executive abilities adversely and the question remains whether such effects are reversible.
CONCLUSION: Though scant, neuropsychological evidence does not seriously contradict current British and German recommendations for dietary control in phenylketonuria.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11043151     DOI: 10.1007/pl00014390

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  3 in total

1.  Health-related quality of life in children and adolescents with phenylketonuria: unimpaired HRQoL in patients but feared school failure in parents.

Authors:  Eva Thimm; Lisa Elena Schmidt; Katrin Heldt; Ute Spiekerkoetter
Journal:  J Inherit Metab Dis       Date:  2013-01-08       Impact factor: 4.982

2.  Executive dysfunction in treated phenylketonuric patients.

Authors:  Bahare Azadi; Arshia Seddigh; Mehdi Tehrani-Doost; Javad Alaghband-Rad; Mahmoud Reza Ashrafi
Journal:  Eur Child Adolesc Psychiatry       Date:  2009-02-16       Impact factor: 4.785

3.  Evaluation of quality of life and description of the sociodemographic state in adolescent and young adult patients with phenylketonuria (PKU).

Authors:  Eva Simon; Martin Schwarz; Judith Roos; Nico Dragano; Max Geraedts; Johannes Siegrist; Gudrun Kamp; Udo Wendel
Journal:  Health Qual Life Outcomes       Date:  2008-03-26       Impact factor: 3.186

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.